FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 311:496-501 August 23, 1984 Number 8 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We evaluated the immunogenicity and efficacy of hepatitis B vaccine (Heptavax-B) in a randomized, double-blind, placebo-controlled trial involving 1311 patients receiving hemodialysis in the United States. After three doses of vaccine (40 micrograms each) had been administered, 63 per cent of the patients were antibody-positive. After correction for possible passive transfer of antibodies by blood transfusion, only 50 per cent of vaccine recipients were considered vaccine responders. The incidence of hepatitis B viral infection during the 25 months of the trial was much lower than had been anticipated and was virtually the same in the vaccine and placebo recipients (6.4 and 5.4 per cent, respectively). Four cases of hepatitis B occurred in patients who had an apparent antibody response to the vaccine, but in each case either antibody had reached low or undetectable levels before hepatitis B surface antigen was detected or the patient had been receiving immunosuppressive therapy. This study did not demonstrate the efficacy of the vaccine in a population of patients receiving dialysis in whom both the rate of antibody response to hepatitis B vaccine and the viral attack rate were low. Other measures to control transmission of hepatitis B virus in dialysis units, including surveillance for hepatitis B surface antigen and isolation of patients who are positive for the antigen, must be continued.

This article has been cited by other articles:

• Litjens, N. H. R., Huisman, M., van den Dorpel, M., Betjes, M. G. H. (2008). Impaired Immune Responses and Antigen-Specific Memory CD4+ T Cells in Hemodialysis Patients. J. Am. Soc. Nephrol. 19: 1483-1490 [Abstract] [Full Text]  
• Verkade, M. A., van Druningen, C. J., Vaessen, L. M. B., Hesselink, D. A., Weimar, W., Betjes, M. G. H. (2007). Functional impairment of monocyte-derived dendritic cells in patients with severe chronic kidney disease. Nephrol Dial Transplant 22: 128-138 [Abstract] [Full Text]  
• Thanavala, Y., Mahoney, M., Pal, S., Scott, A., Richter, L., Natarajan, N., Goodwin, P., Arntzen, C. J., Mason, H. S. (2005). Immunogenicity in humans of an edible vaccine for hepatitis B. Proc. Natl. Acad. Sci. USA 102: 3378-3382 [Abstract] [Full Text]  
• Karayiannis, P., Main, J., Thomas, H. C. (2004). Hepatitis vaccines. Br Med Bull 70: 29-49 [Full Text]  
• Eardley, K. S., Jones, H. E., Osman, H., Smith, S. A. (2002). Efficacy of the accelerated hepatitis B vaccination schedule used in haemodialysis patients post-exposure to virus: a single-centre experience. Nephrol Dial Transplant 17: 1982-1987 [Abstract] [Full Text]  
• Fleischmann, E. H., Kruppenbacher, J., Bock, H. L., Weber, M. (2002). Active immunization against hepatitis A in dialysis patients. Nephrol Dial Transplant 17: 1825-1828 [Abstract] [Full Text]  
• Meier, P., Dayer, E., Blanc, E., Wauters, J.-P. (2002). Early T Cell Activation Correlates with Expression of Apoptosis Markers in Patients with End-Stage Renal Disease. J. Am. Soc. Nephrol. 13: 204-212 [Abstract] [Full Text]  
• Fernandez-Fresnedo, G., Ramos, M. A., Gonzalez-Pardo, M. C., de Francisco, A. L. M., Lopez-Hoyos, M., Arias, M. (2000). B lymphopenia in uraemia is related to an accelerated in vitro apoptosis and dysregulation of Bcl-2. Nephrol Dial Transplant 15: 502-510 [Abstract] [Full Text]  
• Le Meur, Y., Lorgeot, V., Aldigier, J.-C., Wijdenes, J., Leroux-Robert, C., Praloran, V. (1999). Whole blood production of monocytic cytokines (IL-1{beta}, IL-6, TNF-{alpha}, sIL-6R, IL-1Ra) in haemodialysed patients. Nephrol Dial Transplant 14: 2420-2426 [Abstract] [Full Text]  
• Regan, L. S. (1989). Screening for Hepatocellular Carcinoma in High-Risk Individuals: A Clinical Review. Arch Intern Med 149: 1741-1744 [Abstract]  
• Hibberd, P. L., Rubin, R. H. (1989). Immunization Strategies for the Immunocompromised Host: The Need for Immunoadjuvants. ANN INTERN MED 110: 955-956 [Abstract]  
• Wainwright, R. B., McMahon, B. J., Bulkow, L. R., Hall, D. B., Fitzgerald, M. A., Harpster, A. P., Hadler, S. C., Lanier, A. P., Heyward, W. L. (1989). Duration of Immunogenicity and Efficacy of Hepatitis B Vaccine in a Yupik Eskimo Population. JAMA 261: 2362-2366 [Abstract]  
• Kuo, G, Choo, Q., Alter, H., Gitnick, G., Redeker, A., Purcell, R., Miyamura, T, Dienstag, J., Alter, M., Stevens, C., et, al. (1989). An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244: 362-364 [Abstract]  
• Reese, C. E., Ockner, R. K. (1989). Prevention of Hepatitis B in Surgeons and Their Patients. PERSPECT VASC SURG ENDOVASC THER 2: 138-147  
• WILLIAMS, W. W., HICKSON, M. A., KANE, M. A., KENDAL, A. P., SPIKA, J. S., HINMAN, A. R. (1988). Immunization Policies and Vaccine Coverage Among Adults: The Risk for Missed Opportunities. ANN INTERN MED 108: 616-625 [Abstract]  
• HOROWITZ, M. M., ERSHLER, W. B., MCKINNEY, W. P., BATTIOLA, R. J. (1988). Duration of Immunity After Hepatitis B Vaccination: Efficacy of Low-Dose Booster Vaccine. ANN INTERN MED 108: 185-189 [Abstract]  
• (1987). Update on Hepatitis B Prevention: Recommendations of the Immunization Practices Advisory Committee. ANN INTERN MED 107: 353-357 [Abstract]  
• (1987). Leads From the MMWR. JAMA 258: 437-449  
• Stevens, C. E., Taylor, P. E., Tong, M. J., Toy, P. T., Vyas, G. N., Nair, P. V., Weissman, J. Y., Krugman, S. (1987). Yeast-Recombinant Hepatitis B Vaccine: Efficacy With Hepatitis B Immune Globulin in Prevention of Perinatal Hepatitis B Virus Transmission. JAMA 257: 2612-2616 [Abstract]  
• Hollinger, F. B. (1987). Hepatitis B Vaccines--to Switch or Not to Switch. JAMA 257: 2634-2636 [Abstract]  
• Raskova, J., Ghobrial, I., Czerwinski, D. K., Shea, S. M., Eisinger, R. P., Raska, K. Jr (1987). B-Cell Activation and Immunoregulation in End-Stage Renal Disease Patients Receiving Hemodialysis. Arch Intern Med 147: 89-93 [Abstract]  
• CRAVEN, D. E., AWDEH, Z. L., KUNCHES, L. M., YUNIS, E. J., DIENSTAG, J. L., WERNER, B. G., POLK, B. F., SNYDMAN, D. R., PLATT, R., CRUMPACKER, C. S., GRADY, G. F., ALPER, C. A. (1986). Nonresponsiveness to Hepatitis B Vaccine in Health Care Workers: Results of Revaccination and Genetic Typings. ANN INTERN MED 105: 356-360 [Abstract]  
• SHERRARD, D. J. (1986). Recommendations for Viral Hepatitis. ANN INTERN MED 104: 132-134 [Abstract]  
• Weber, D. J., Rutala, W. A., Samsa, G. P., Santimaw, J. E., Lemon, S. M. (1985). Obesity as a Predictor of Poor Antibody Response to Hepatitis B Plasma Vaccine. JAMA 254: 3187-3189 [Abstract]  
• Troisi, C. L., Heiberg, D. A., Hollinger, F. B. (1985). Normal Immune Response to Hepatitis B Vaccine in Patients With Down's Syndrome: A Basis for Immunization Guidelines. JAMA 254: 3196-3199 [Abstract]  
• Alter, M. J., Favero, M. S., Maynard, J. E. (1985). Hepatitis B Vaccine Use in Chronic Hemodialysis Centers in the United States. JAMA 254: 3200-3202 [Abstract]  
• (1985). Recommendations for Protection Against Viral Hepatitis: Recommendation of the Immunization Practices Advisory Committee. ANN INTERN MED 103: 391-402 [Abstract]  
• (1985). Leads from the MMWR. JAMA 254: 197-217  
• Lelie, P. N., Reesink, H. W., de Jong-van Manen, S. Th., Dees, P. J., Reerink-Brongers, E. E. (1985). Immune Response to a Heat-Inactivated Hepatitis B Vaccine in Patients Undergoing Hemodialysis: Enhancement of the Response by Increasing the Dose of Hepatitis B Surface Antigen From 3 to 27 {micro}g. Arch Intern Med 145: 305-309 [Abstract]